全文获取类型
收费全文 | 1015256篇 |
免费 | 88594篇 |
国内免费 | 64907篇 |
专业分类
耳鼻咽喉 | 9406篇 |
儿科学 | 12454篇 |
妇产科学 | 13204篇 |
基础医学 | 106704篇 |
口腔科学 | 17879篇 |
临床医学 | 135642篇 |
内科学 | 134450篇 |
皮肤病学 | 10268篇 |
神经病学 | 47298篇 |
特种医学 | 36229篇 |
外国民族医学 | 459篇 |
外科学 | 95395篇 |
综合类 | 193585篇 |
现状与发展 | 200篇 |
一般理论 | 87篇 |
预防医学 | 78810篇 |
眼科学 | 26129篇 |
药学 | 109850篇 |
1064篇 | |
中国医学 | 66501篇 |
肿瘤学 | 73143篇 |
出版年
2024年 | 3066篇 |
2023年 | 12752篇 |
2022年 | 33539篇 |
2021年 | 43052篇 |
2020年 | 33579篇 |
2019年 | 27409篇 |
2018年 | 29681篇 |
2017年 | 29091篇 |
2016年 | 26318篇 |
2015年 | 41134篇 |
2014年 | 52548篇 |
2013年 | 51219篇 |
2012年 | 74509篇 |
2011年 | 82998篇 |
2010年 | 58799篇 |
2009年 | 48484篇 |
2008年 | 58994篇 |
2007年 | 61461篇 |
2006年 | 60060篇 |
2005年 | 54700篇 |
2004年 | 37818篇 |
2003年 | 35757篇 |
2002年 | 30774篇 |
2001年 | 26143篇 |
2000年 | 24639篇 |
1999年 | 23669篇 |
1998年 | 14308篇 |
1997年 | 14143篇 |
1996年 | 11083篇 |
1995年 | 10217篇 |
1994年 | 8566篇 |
1993年 | 5533篇 |
1992年 | 7185篇 |
1991年 | 6094篇 |
1990年 | 5199篇 |
1989年 | 4444篇 |
1988年 | 3969篇 |
1987年 | 3427篇 |
1986年 | 2819篇 |
1985年 | 2258篇 |
1984年 | 1375篇 |
1983年 | 965篇 |
1982年 | 591篇 |
1981年 | 573篇 |
1980年 | 466篇 |
1979年 | 635篇 |
1978年 | 266篇 |
1977年 | 247篇 |
1974年 | 272篇 |
1973年 | 247篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
43.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
44.
肝门部胆管癌(hilar cholangiocarcinoma,HC)分型和分期系统较为庞杂,包括改良Bismuth-Corlette分型,Gazzaniga T分期,Blumgart T分期,美国纪念Sloan-Kattering癌症中心(Memorial Sloan Katering Cancer Center,MSKCC)T分期,Mayo分期系统,美国癌症联合委员会(American Joint Committee on Cancer,AJCC)和国际抗癌联盟(International Union Against Cancer,UICC)联合发布的TNM分期,欧洲肝胆胰协会分期(Consensus classification from the European Hepato-Pancreato-Biliary Association,EHPBA),以及日本肝胆胰外科学会(Japanese Society of Hepato-Biliary-Pancreatic Surgery,JSHBPS)分期,各分期系统所包含的内容差异较大,各具特色和优缺点,本文就HC常见的分型和分期系统及其在临床中的应用价值做一综述。 相似文献
46.
47.
Anatoly E Martynyuk Ling-Sha Ju Timothy E Morey Jia-Qiang Zhang 《World Journal of Psychiatry》2020,10(5):81-94
The progress of modern medicine would be impossible without the use of general anesthetics (GAs). Despite advancements in refining anesthesia approaches, the effects of GAs are not fully reversible upon GA withdrawal. Neurocognitive deficiencies attributed to GA exposure may persist in neonates or endure for weeks to years in the elderly. Human studies on the mechanisms of the long-term adverse effects of GAs are needed to improve the safety of general anesthesia but they are hampered not only by ethical limitations specific to human research, but also by a lack of specific biological markers that can be used in human studies to safely and objectively study such effects. The latter can primarily be attributed to an insufficient understanding of the full range of the biological effects induced by GAs and the molecular mechanisms mediating such effects even in rodents, which are far more extensively studied than any other species. Our most recent experimental findings in rodents suggest that GAs may adversely affect many more people than is currently anticipated. Specifically, we have shown that anesthesia with the commonly used GA sevoflurane induces in exposed animals not only neuroendocrine abnormalities (somatic effects), but also epigenetic reprogramming of germ cells (germ cell effects). The latter may pass the neurobehavioral effects of parental sevoflurane exposure to the offspring, who may be affected even at levels of anesthesia that are not harmful to the exposed parents. The large number of patients who require general anesthesia, the even larger number of their future unexposed offspring whose health may be affected, and a growing number of neurodevelopmental disorders of unknown etiology underscore the translational importance of investigating the intergenerational effects of GAs. In this mini review, we discuss emerging experimental findings on neuroendocrine, epigenetic, and intergenerational effects of GAs. 相似文献
48.
49.
50.